Kornimate/medical-research-clean huggingface dataset:
clinical investigation evaluating the safety and feasibility of adipearl

Conditions: Mid-face Volume Deficiency

Summary: adipearl is an injectable filler intended to be injected subcutaneously in the face.


Eligibility criteria:
inclusion criteria: * subject having given freely and expressly informed consent; * subject deemed by the investigator to be medically fit for injection of the product; * female or male subjects aged 22 to 65 years (inclusive); exclusion criteria: * pregnant or nursing woman or planning a pregnancy during the study. * subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship. * subject participating to another research study. * subject with the presence of any condition, which in the opinion of the principal investigator, that makes her/him unable to complete the study per protocol.
effect of core stability exercises on pain and quality of life in non specific low back pain

Conditions: Non Specific Low Back Pain

Summary: most publications state that core stability exercises (transverse abdominis and multifidus training) can relieve chronic low back pain with or without radiculopathy and improve function, although only temporarily, and may have the same impact as active general exercise so the goal of this study is to detect the effect of retraining the deep core muscles, on pain, disability, and quality of life in patients with chronic non specific low back pain.

the goal of this study is to detect the effect of retraining the deep core muscles, on pain, disability, and quality of life in patients with chronic non specific low back pain this study is delimited to the following aspects: 1. fifty, patients of only females with chronic non specific low back pain more than 3 months. 2. the age will range from 22 to 45 years. 3. the treatment will conduct to three session per week for four weeks . 4. the selected patients will assigned randomly to two equal groups: 1- group1 (intervention), will do the selected treatment that include electrical stimulation in addition to core stability exercises program. 2- group2(control), will do the conventional treatment only.

Eligibility criteria:
inclusion criteria: * gender is women * age ranges from 22 to45 years old * chronic non specific low back pain for at least 3 month * pain score will between 3 to 6 on visual analogue scale exclusion criteria: * any deformity of the spine * red flags including serious pathology * systemic or inflammatory disease * sever osteoporosis * history of tumor or cancer * spine infection * history of spine or pelvis surgery or fracture * cauda equina syndrome * progressive neurological deficit * severe instability * sever cardio vascular or metabolic disease * history of psychological disease * anatomical and congenital disturbance * continuous pain more than 8 on (visual analogue scale)
myo-inositol- based co-treatment in women with pcos undergoing assisted reproductive technology

Conditions: Sterility; Infertility

Summary: this is a prospective comparative randomized controlled study investigating the effect of myo-inositol-based co-treatment on oocyte quality measures in women with pcos.

polycystic ovary syndrome is the most common cause of chronic anovulation in women. women with pcos undergoing ivf are at an increased risk for developing both multiple gestation and ovarian hyperstimulation syndrome (ohss). since insulin resistance and hyperinsulinemia have been implicated in the pathophysiology of the disorder, the administration of metformin before or during an ivf cycle has been practiced for years in an attempt to improve follicular parameters necessary for reproductive success. recently, a growing body of evidence has implicated alternative insulin sensitizing drugs, namely myo-inositol, in improving various manifestations of the disorder in this women population. little has been done to evaluate the effect of myo-inositol co-treatment on the reproductive performance of pcos women undergoing assisted reproductive technologies (art). in this prospective comparative randomized controlled study, women will be randomized into two groups: women in the control group will receive folic acid daily. women in the study group will receive myo-inositol, in combination with alpha- lipoic acid and cysteine, per day plus folic acid supplemented daily along with ovarian stimulation.

Eligibility criteria:
inclusion criteria: * age 18-40 years at the time of enrollment. * women diagnosed with pcos according to the rotterdam criteria indicated by oligoamenorrhea (six or fewer menstrual cycles during a period of 1 year), hyperandrogenism (hirsutism, acne, or alopecia) or hyperandrogenemia (elevated levels of total or free t) and typical features of ovaries on ultrasound scan. * planned ivf/icsi treatment. * normal uterine cavity (as assessed by hysteroscopy or hsg). * normal hormonal investigation: tsh and prl. exclusion criteria: * azoospermia. * other medical conditions causing ovulatory disorders, such as hyperprolactinemia, hypothyroidism, or adrenal hyperplasia. * hypersensitivity to myo-inositol or its derivatives.

Keywords: polycystic ovary syndrome myo-inositol assisted reproductive technology oocyte performance pregnancy
exercise interventions in parkinson's disease

Conditions: Parkinson's Disease

Summary: this study sets out to determine the effect of exercise performed over a longer period of time (6 months), delivered using community facilities, on motor and non motor symptoms, health and well being in people with parkinson's disease.

participation in exercise is beneficial for health and well being, but the effect over a longer period of time in people with parkinson's disease (pd) has not been established. people with pd currently only receive short-term support for exercise therapy interventions funded from the national health service; it is therefore unsurprising that people with pd are observed to have low levels of physical activity that decrease over time. using mixed methodology the investigators will explore the effect of exercise delivered over a longer period of time (six months) in people with pd. the investigators will examine the views of people participating in the program. aims using a randomized controlled trial with one intervention arm and an active comparator control group with blinded assessments and semi-structured interview techniques the investigators will determine in people with pd: 1. the effect of longer-term exercise participation on motor symptoms 2. the effect of longer-term exercise participation on non motor symptoms, fitness, health and well being. 3. participants views of the process and sustainability of community provision of exercise over a longer period of time.

Eligibility criteria:
inclusion criteria: * parkinson's disease diagnosed by neurological examination; idiopathic pd defined by the uk parkinson's disease society brain bank criteria * able to walk ≥ 100m * maintained a stable medical regime for 12 weeks prior to initiation of the study, and anticipated to maintain a stable regime for the course of study (as determined by the referring clinician). exclusion criteria: * dementia * history of additional prior neurological condition * severe depression or psychosis or a mental state that would preclude consistent active involvement with the study over its duration * cardiac precautions that would prevent the subject from completing the exercise program or the full battery of outcome measures * any known contraindication to exercise * reduced cognition of any cause \[minimental state examination \[(mmse) \< 23\] * an orthopaedic condition that independently limits walking;

Keywords: parkinson's disease exercise treatment outcome patient adherence
the investigation of predicting mortality and morbidity in patients admitted to intensive care unit with thoracic trauma using selected biomarkers and parameters

Conditions: Thorax Traumas

Summary: this prospective study aimed to predict morbidity and mortality after thoracic trauma in intensive care unit evaluated clinical and biochemical data of 50 intensive care unit patients. the research examined demographic factors such as gender, age, and smoking status, trauma scoring systems like iss and rts as well as biomarkers such as surfactant-d and oxygenation parameters including the rox index, pao₂/fio₂ ratio and fio₂.


Eligibility criteria:
inclusion criteria: * patients with thoracic trauma between the ages of 18-85 * patients who have been monitored in intensive care for at least 1 week exclusion criteria: * being outside the age range of 18-85 * pregnant patients * patients whose intensive care follow-up lasted less than 1 week * patients who do not want to be included in the study * patients with a lung malignancy diagnosis before admission

Keywords: thorax trauma rox index surfactant-d
postural habits, awareness and spine

Conditions: Spine; Posture

Summary: alterations in posture are frequently seen as a risk factor for the development of spine pain. postural awareness is essential for sustaining healthy postural habits in daily life. the first of the contribution to literature of our study is that the postural habits and awareness scale, which is a new questionnaire that provides easy inquiry about postural habits and awareness, is a low-cost method and has not been used in the literature before, was used to confirm the relationships between spine pain and functionality and scale parameters in accordance with the literature. another contribution is that it is underlined that even among doctors, who are the direct managers of health, low postural awareness and bad postural habits that can lead to spinal problems are quite common.


Eligibility criteria:
inclusion criteria: * participants between the ages of 20-50 * who were working as research assistant physicians exclusion criteria: * with a history of previous trauma or surgery that could cause pain or postural disorders in the spine, * known systemic, neurological, psychiatric, infectious, inflammatory, rheumatic, tumoral or degenerative diseases
a study of supaglutide in chinese type 2 diabetes patients

Conditions: Diabetes Mellitus, Type 2

Summary: a study on the safety, efficacy, pharmacokinetics and pharmacodynamics of supaglutide dosing weekly and bi-weekly in patients with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: 1. have diagnosed with type 2 diabetes for at least 3 months before enrollment. 2. have diet and exercise intervention only (for part a and part b) or been treated with stable dose of metformin as monotherapy for at least 3 months (for part b only) 3. have hba1c ≥7.0% and ≤10.0% as assessed by the central laboratory. 4. have a body mass index (bmi) of 20-40 kilograms per square meter (kg/m\^2). exclusion criteria: 1. type 1 diabetes (t1d). 2. evidences of fasting c-peptide levels\<0.81 ng/ml. 3. history of trauma, infection or surgery within a month; 4. history of blood donation, blood transfusion or losing more than 450 ml blood within 3 months. 5. history of the severe cardiovascular conditions, gastrointestinal diseases, blood system diseases, pancreatitis, or malignant tumors. 6. evidence of abnormal thyroid function within 6 months before screening. 7. positive test results in hbsag, hcvab, hivab or tpab. 8. history of serious mental illness. 9. history of drug or alcohol abuse. 10. history of a transplanted organ, acquired or congenital immune system diseases. 11. allergy to active ingredients or excipients of the test drug. 12. evidence of abnormal result of laboratory examination according to the judgment of researchers. 13. participated in any interventional medical, surgical, or pharmaceutical study within 3 months prior to entry into the study. 14. previously completed or withdrawn from this study after providing informed consent.
a multi-centered，randomized，double-blind，placebo-controlled study to evaluate the efficacy and safety of shr-1703 in eosinophilic asthma

Conditions: Asthma With Eosinophilic Phenotype

Summary: the purpose of this study is to evaluate the pharmacodynamic, efficacy and safety of shr-1703 in asthma patients with eosinophil phenotype


Eligibility criteria:
inclusion criteria: 1. at least 12 years of age 2. a minimum weight of 40kg 3. a medical history of at least 1 year that meets the diagnosis of asthma; 4. current treatment with medium- or high- doses of ics for at least 6 months and using steadily at least 3 months 5. current treatment with an additional controller medication, besides ics, for at least 3 months and using steadily at least 1 month 6. absolute count of blood eosinophils suggests eosinophilic asthma 7. during the screening period and baseline, pre- bd fev1% \< 80% 8. during the screening period and baseline, acq-6 score indicates asthma poor control 9. history of severe asthma exacerbation within the past 12 months prior to screening 10. good compliance with ediary completion 11. take efficient contraceptive measures 12. voluntarily sign the informed consent form to participate in this study exclusion criteria: 1. with other condition that could lead to elevated eosinophils 2. with clinically significant pulmonary diseases 3. with existing immunodeficiency disease 4. with other clinically significant diseases that may affect lung function 5. with uncontrolled severe cardiovascular and cerebrovascular diseases 6. with uncontrolled hypertension and/or diabetes 7. with exacerbation, allergic rhinitis or sinusitis attacks, or clinical significant infection requiring intervention during 4 weeks prior to randomization 8. recent major surgeries or surgical plans during the study period, or treatment measures that investigators believe may affect subject evaluation 9. existing parasitic infections 10. diagnosed as malignant tumor within the first 5 years of randomization 11. significant abnormalities in screening period or baseline laboratory tests 12. screening period or baseline ecg qtc prolongation 13. prohibited drugs using during the pre randomization period 14. participated in other clinical trials within 30 days prior to screening and used research drugs containing active ingredients, or was still within 5 half lives of the research drug at the time of screening 15. smoking or quitting smoking for less than 6 months during screening, or previous smoking history ≥ 10 pack years 16. history of drug use, alcoholism, or substance abuse within the past year prior to screening 17. allergic or intolerant to il-5 monoclonal antibodies or other biological agents 18. pregnant or lactating subjects 19. other reasons why the researcher deemed it unsuitable for conducting this experiment
combined aerobic and resistance exercise training in metastatic renal cell carcinoma

Conditions: Renal Cell Carcinoma Metastatic

Summary: the trial studies the effects of personalized home-based aerobic and resistance exercises on quality of life, changes in physical activity levels, and the change in inflammatory myokines with the exercise intervention in interleukin 6 (il-6), c-reactive protein (crp), leptin, transforming growth factor beta (tgf-beta), and interferon (inf) gamma.


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of rcc * patients being treated with standard of programmed cell death protein 1 (anti-pd-1) or anti-pd-l1 immune-checkpoint inhibitor-containing standard of care regimen including patients who are about to start treatment or have been on treatment for a maximum of 4 weeks prior to signing consent * metastatic measurable disease, as defined by recist 1.1 * eastern cooperative oncology group (ecog) performance status of 0-2 with a life expectancy ≥ six months * physically able to enroll in the exercise program as determined by the treating medical oncologist and after review by physical medicine and rehabilitation physicians at johns hopkins * adequate bone marrow reserve and organ function measured within 28 days prior to administration of study treatment with the following key parameters: * hematological: * absolute neutrophil count ≥ 1.5 × 109/l * platelets ≥ 100 × 109/l * hemoglobin≥ 9.0 g/dl * renal: * serum creatinine ≤ 1.5 x the upper limit of normal (uln) or calculated creatinine clearance ≥ 30ml/min * hepatic: * total bilirubin ≤ 1.5 x uln (patients with known gilbert disease who have serum bilirubin level ≤ 3 x uln may be enrolled) * serum aspartate aminotransferase (ast) and serum alanine aminotransferase (alt) ≤ 2.5 x uln (for patients with documented liver metastases ast and/or alt ≤ 5 x uln) exclusion criteria: * the presence of bone metastasis in the spine, pelvis, and lower limbs * currently physically active or moderately active as determined by leisure score index of godin leisure-time exercise questionnaire (gsltpaq) * history of underlying cardiovascular, respiratory, musculoskeletal disease or joint problems that preclude moderate physical activity * known underlying uncontrolled brain metastatic lesions requires steroids therapy and/or radiotherapy * major surgery within four weeks prior to enrollment. * radiotherapy for rcc 28 days prior to week 1 day 1
motivating structured walking activity in intermittent claudication

Conditions: Peripheral Arterial Disease; Intermittent Claudication; Peripheral Vascular Disease

Summary: peripheral arterial disease can cause leg pain or discomfort (called intermittent claudication (ic)), which limits the ability to walk and carry out everyday activities. lifestyle changes, like increasing walking, can lead to improvements, but can be a challenge to begin and then continue. the aim of this study is to investigate if a physiotherapist-led, behaviour change treatment effects walking in people with ic. the treatment is designed to build an understanding of ic and walking exercise and help individuals develop strategies to increase regular walking. the trial will recruit 192 adults (aged 50 years and over) with ic. all participants will visit king's college london or their local hospital to complete two short walking tests and answer questionnaires about their daily activities, beliefs about their symptoms and treatment, quality of life and the costs of having ic. participants will then be randomly assigned to receive either the new treatment or continue with their usual nhs care. the new treatment involves two 60-minute face-to-face sessions (at the participant's home or local hospital) and two 20-minute telephone calls with a physiotherapist who will discuss participants' understanding and beliefs about ic, walking and help participants to set goals and plans to increase walking over 12 weeks. participants will be provided with a step counter (pedometer) and walking record. after 12 weeks, all participants will attend a second appointment where they will repeat the walking tests and fill out another set of questionnaires. a final set of questionnaires will be completed by all participants after 6 months (by post or electronically). some participants will be invited to provide feedback on their experience of the treatment and trial by telephone or a face-to-face interview with a researcher.


Eligibility criteria:
inclusion criteria: * ≥50 years of age; * established pad (ankle brachial pressure index ≤0.90 and/or radiographic evidence or clinician reported diagnosis) and ic (presence of symptoms reported on the san diego claudication questionnaire) * able to participate in mosaic * able and willing to provide informed consent exclusion criteria: * unstable ic (self-reported change in symptoms during previous 3 months) * walking \>90 minutes/week (reported on brief international physical activity questionnaire * contraindications to walking exercise (e.g., unstable angina) confirmed by their vascular specialist * have completed any prescribed supervised exercise sessions in the previous 6 months or been offered prescribed exercise sessions in the next 6 months.

Keywords: walking six-minute walk distance illness perceptions theory of planned behaviour
future leaders program: testing a youth civic leadership, engagement, and mindfulness program

Conditions: Adolescent Behavior Problem; Mental Health Wellness 1

Summary: the current study tests the feasibility and effectiveness of a youth intervention designed to provide meaningful leadership opportunities and to address barriers to equity, through the acquisition of civic leadership and development skills as well as mindfulness practice, leap: leadership, engagement, and youth activism program with mindfulness. the goal of this project is to determine whether the leadership, engagement, and youth activism program with mindfulness (leap) curriculum, which was developed with youth of color, is a feasible and effective intervention for fostering civic leadership, civic development, and wellbeing. the investigators seek to understand whether leap can support wellbeing for youth of color as a strategy to increase youth mental, emotional, and behavioral (meb) health and decrease health disparities in youth of color.

the leap study will determine whether a 14-session program designed to provide leadership and mindfulness skills to youth of color is an effective and feasible intervention. the curriculum consists of 14 two-hour sessions delivered after school. the comparison group will take part in envisionit, a college and career readiness program designed for students in grades 6 through 12. envisionit aims to prepare students with essential transition skills, digital literacy, and college and career readiness. the comparison group will also have 14 two-hour group sessions. both leap and envisionit will be delivered by trained facilitators. all participants in leap and envisionit will be assessed at four time points assessing program outcomes; facilitators will also complete interviews post-intervention and provide feedback on data fidelity and acceptability following each session. this record reports on the uh3 phase of the grant.

Eligibility criteria:
inclusion criteria: * adolescents ages 14 and older in grades 9-12 during the fall/winter or in grades 9-11 during the spring * enrolled in a partner site in ma or chicago, il * adolescents are only included with parent consent and youth assent if they are under the age of 18. adolescents at least 18 years old can provide consent. exclusion criteria: * they participated in the pilot phase (ug3) * they cannot commit to participation in the full study (e.g., attendance at all intervention sessions) * they are not in grades 9-12 at a partner site * parent/guardian has a preferred consent language other than english or spanish.

Keywords: mindfulness civic engagement civic action youth leadership youth wellbeing
determinants of compliance with glaucoma therapy

Conditions: Open Angle Glaucoma

Summary: to determine the association between medical, demographic, socioeconomic, and therapeutic differences on compliance with topical glaucoma therapy using the travalert device.

to determine the association between medical, demographic, socioeconomic, and therapeutic differences on compliance with topical glaucoma therapy using the travalert device. all participants will have open angle glaucoma.

Eligibility criteria:
to be eligible to participate in the study, patients had to be (1) 19 years or older; (2) have a diagnosis of open angle glaucoma (oag) in 1 or both eyes or ocular hypertension; and (3) using a prostaglandin ocular hypotensive medication in 1 or both eyes. the protocol excluded patients with uncontrolled iop control, known contraindications to travoprost, clinically significant systemic disease that would interfere with the study, participation in any other research study within 30 days, or change in systemic medications that may alter iop within 30 days before recruitment.

Keywords: travalert open angle glaucoma